Barcelona
(CNA).- The Catalan company AB-BIOTICS, devoted to the protection and
distribution of biotechnological solutions to improve health and welfare has
presented advance results of its 2010 fiscal year to the Alternative Stock
Market, where it quotes since July 2010. The company closed the period with a
total income of € 6,162,911, an increase of 71% over the previous year. The
CEOs and co-founders of the company, Miquel Angel Bonachera and Sergi
Audivert, explained that given “the national economic situation they can
be proud of these results, but AB-BIOTICS aims to become an international
reference”.
The
economic crisis has not stopped the growth of AB-BIOTICS revenues. This
increase is due to expansion in all three business areas in which the company
is divided. Firstly, genetics, which basically takes care of pharmacology
studies. Secondly, R & D Partnering, which comes from the integrated
management of research projects for the pharmaceutical and food industry.
Finally, Functional Ingredients, which develop medical substances (probiotics
and other nutraceuticals) to prevent and treat diseases.
However, this is only the beginning of an ambitious scheme. In December 2010, AB-BIOTICS finalized a capital increase of € 4.3 million, which will enable them to implement the first phase of the international expansion plan of the company. The purpose is to be present in various European and American markets with immense potential for its products. Bonachera and Audivert, explained that their “business plan anticipated that most revenue will come from foreign markets over the coming years”.
However, this is only the beginning of an ambitious scheme. In December 2010, AB-BIOTICS finalized a capital increase of € 4.3 million, which will enable them to implement the first phase of the international expansion plan of the company. The purpose is to be present in various European and American markets with immense potential for its products. Bonachera and Audivert, explained that their “business plan anticipated that most revenue will come from foreign markets over the coming years”.
Cap comentari:
Publica un comentari a l'entrada